BMJ 1998;316:1127-1130 ( 11 April )

Papers

Baseline serum cholestanol as predictor of recurrent coronary events in subgroup of Scandinavian simvastatin survival study

Tatu A Miettinen, professor, a Helena Gylling, senior physician, a Timo Strandberg, assistant professor, a Seppo Sarna, associate professor, b for the Finnish 4S Investigators.

a Department of Medicine, Division of Internal Medicine, University of Helsinki, FI-00290 Helsinki, Finland, b Department of Public Health, University of Helsinki

Correspondence to: Dr Miettinen tatu.a.miettinen{at}helsinki.fi

Objectives: To investigate whether baseline serum cholestanol:cholesterol ratio, which is negatively related to cholesterol synthesis, could predict reduction of coronary events in the Scandinavian simvastatin survival study.
Design: Follow up of patients with coronary heart disease in whom baseline ratios were related to major coronary events.
Setting: Four universities in Finland.
Subjects: A subgroup of 868 patients with coronary heart disease selected from the Scandinavian simvastatin survival study.
Intervention: Treatment with simvastatin or placebo.
Main outcome measures: Serum concentrations of low density lipoprotein and high density lipoprotein cholesterol, total triglyceride concentration, and cholesterol:cholestanol ratio. Major coronary events.
Results: With increasing baseline quarter of cholestanol distribution the reduction in relative risk increased gradually from 0.623 (95% confidence interval 0.395 to 0.982) to 1.166 (0.791 to 1.72). The risk of recurrence of major coronary events increased 2.2-fold (P<0.01) by multiple logistic regression analysis between the lowest and highest quarter of cholestanol. The ratio of cholestanol was related inversely to the body mass index and directly to high density lipoprotein cholesterol and triglyceride concentrations but their quarters of distribution were not related to risk reduction.
Conclusions: Measurement of serum cholestanol concentration revealed a subgroup of patients with coronary heart disease in whom coronary events were not reduced by simvastatin treatment. Thus, patients with high baseline synthesis of cholesterol seem to be responders whereas those with low synthesis of cholesterol are non-responders.

Key messages

  • Recurrence of major coronary events is reduced by statin treatment in about one third of patients with coronary heart disease, to predict those who will not respond has not been possible from baseline lipid concentrations in the Scandinavian simvastatin survival.

  • This study showed that increasing quarters of cholestanol:cholesterol ratio, reflecting decreasing synthesis of cholesterol, were related to recurrence of major coronary events during simvastatin treatment in a Finnish subgroup (n=868) of the Scandinavian study.

  • The subjects with lowest baseline quarters of cholestanol were associated with significantly reduced relative risk of major coronary events, while the risk in the highest quarter was unchanged and 2.2 times higher than in the lowest one.

  • Cholestanol:cholesterol ratios were related inversely to the body mass index and directly to high density lipoprotein cholesterol and triglyceride concentrations, but their quarters were unrelated to risk reduction.

  • The findings suggest that patients with coronary disease who have high absorption (high basal cholestanol:cholesterol) and low synthesis of cholesterol do not benefit from statin treatment alone and that they can be identified by measuring serum cholestanol concentration before treatment.



© BMJ 1998
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?

Relevant Articles

Cholestanol and survival with simvastatin
E J Wallis, R Williamson, L E Ramsay, W W Yeo, P R Jackson, Tatu A Miettinen, Helena Gylling, Timo Strandberg, and Seppo Sarna
BMJ 1998 317: 1252. [Extract] [Full Text]

Baseline serum cholestanol can predict recurrent coronary events
BMJ 1998 316: 0. [Full Text]

This article has been cited by other articles:

  • van Himbergen, T. M., Matthan, N. R., Resteghini, N. A., Otokozawa, S., Ai, M., Stein, E. A., Jones, P. H., Schaefer, E. J. (2009). Comparison of the effects of maximal dose atorvastatin and rosuvastatin therapy on cholesterol synthesis and absorption markers. J. Lipid Res. 50: 730-739 [Abstract] [Full text]  
  • Weingartner, O., Bohm, M., Laufs, U. (2009). Controversial role of plant sterol esters in the management of hypercholesterolaemia. Eur Heart J 30: 404-409 [Full text]  
  • Silbernagel, G., Fauler, G., Renner, W., Landl, E. M., Hoffmann, M. M., Winkelmann, B. R., Boehm, B. O., Marz, W. (2009). The relationships of cholesterol metabolism and plasma plant sterols with the severity of coronary artery disease. J. Lipid Res. 50: 334-341 [Abstract] [Full text]  
  • Bao, L., Li, Y., Deng, S.-X., Landry, D., Tabas, I. (2006). Sitosterol-containing Lipoproteins Trigger Free Sterol-induced Caspase-independent Death in ACAT-competent Macrophages. J. Biol. Chem. 281: 33635-33649 [Abstract] [Full text]  
  • Radermecker, R. P., Scheen, A. J. (2006). Serum Plant Sterols and Atherosclerosis: Is There a Place for Statin-Ezetimibe Combination?. J Am Coll Cardiol 47: 1496-1497 [Full text]  
  • Miettinen, T. A., Railo, M., Lepantalo, M., Gylling, H. (2005). Plant Sterols in Serum and in Atherosclerotic Plaques of Patients Undergoing Carotid Endarterectomy. J Am Coll Cardiol 45: 1794-1801 [Abstract] [Full text]  
  • Plat, J., Bragt, M. C. E., Mensink, R. P. (2005). Common sequence variations in ABCG8 are related to plant sterol metabolism in healthy volunteers. J. Lipid Res. 46: 68-75 [Abstract] [Full text]  
  • Chan, D.C., Watts, G.F., Barrett, P.H.R., Whitfield, A.J., van Bockxmeer, F.M. (2004). ATP-Binding Cassette Transporter G8 Gene As a Determinant of Apolipoprotein B-100 Kinetics in Overweight Men. Arterioscler. Thromb. Vasc. Bio. 24: 2188-2191 [Abstract] [Full text]  
  • Gylling, H., Hallikainen, M., Pihlajamaki, J., Agren, J., Laakso, M., Rajaratnam, R. A., Rauramaa, R., Miettinen, T. A. (2004). Polymorphisms in the ABCG5 and ABCG8 genes associate with cholesterol absorption and insulin sensitivity. J. Lipid Res. 45: 1660-1665 [Abstract] [Full text]  
  • Raggi, P., Callister, T. Q., Shaw, L. J. (2004). Progression of Coronary Artery Calcium and Risk of First Myocardial Infarction in Patients Receiving Cholesterol-Lowering Therapy. Arterioscler. Thromb. Vasc. Bio. 24: 1272-1277 [Abstract] [Full text]  
  • Ben-Yehuda, O. (2004). The cardiologist's toolbox: improving care. J Am Coll Cardiol 43: 2174-2176 [Full text]  
  • Kajinami, K., Brousseau, M. E., Nartsupha, C., Ordovas, J. M., Schaefer, E. J. (2004). ATP binding cassette transporter G5 and G8 genotypes and plasma lipoprotein levels before and after treatment with atorvastatin. J. Lipid Res. 45: 653-656 [Abstract] [Full text]  
  • Kwiterovich, P. O. Jr., Chen, S. C., Virgil, D. G., Schweitzer, A., Arnold, D. R., Kratz, L. E. (2003). Response of obligate heterozygotes for phytosterolemia to a low-fat diet and to a plant sterol ester dietary challenge. J. Lipid Res. 44: 1143-1155 [Abstract] [Full text]  
  • Evans, M., Roberts, A., Rees, A. (2003). Pharmacological management of hyperlipidaemia. British Journal of Diabetes & Vascular Disease 3: 204-210 [Abstract]  
  • Gylling, H., Miettinen, T. A. (2002). Inheritance of cholesterol metabolism of probands with high or low cholesterol absorption. J. Lipid Res. 43: 1472-1476 [Abstract] [Full text]  
  • Berge, K. E., von Bergmann, K., Lutjohann, D., Guerra, R., Grundy, S. M., Hobbs, H. H., Cohen, J. C. (2002). Heritability of plasma noncholesterol sterols and relationship to DNA sequence polymorphism in ABCG5 and ABCG8. J. Lipid Res. 43: 486-494 [Abstract] [Full text]  
  • Thompson, G.R., O'Neill, F., Seed, M. (2002). Why some patients respond poorly to statins and how this might be remedied. Eur Heart J 23: 200-206 [Full text]  
  • Ballantyne, C. M., Olsson, A. G., Cook, T. J., Mercuri, M. F., Pedersen, T. R., Kjekshus, J. (2001). Influence of Low High-Density Lipoprotein Cholesterol and Elevated Triglyceride on Coronary Heart Disease Events and Response to Simvastatin Therapy in 4S. Circulation 104: 3046-3051 [Abstract] [Full text]  
  • Ness, G. C., Chambers, C. M. (2000). Feedback and Hormonal Regulation of Hepatic 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase: The Concept of Cholesterol Buffering Capacity. Exp. Biol. Med. 224: 8-19 [Abstract] [Full text]  
  • Miettinen, T. A., Strandberg, T. E., Gylling, H., Group, f. t. F. I. o. t. S. S. S. S. (2000). Noncholesterol Sterols and Cholesterol Lowering by Long-Term Simvastatin Treatment in Coronary Patients : Relation to Basal Serum Cholestanol. Arterioscler. Thromb. Vasc. Bio. 20: 1340-1346 [Abstract] [Full text]  
  • Rajaratnam, R. A., Gylling, H., Miettinen, T. A. (2000). Independent association of serum squalene and noncholesterol sterols with coronary artery disease in postmenopausal women. J Am Coll Cardiol 35: 1185-1191 [Abstract] [Full text]  
  • Vuorio, A. F., Gylling, H., Turtola, H., Kontula, K., Ketonen, P., Miettinen, T. A. (2000). Stanol Ester Margarine Alone and With Simvastatin Lowers Serum Cholesterol in Families With Familial Hypercholesterolemia Caused by the FH-North Karelia Mutation. Arterioscler. Thromb. Vasc. Bio. 20: 500-506 [Abstract] [Full text]  
  • Wallis, E J, Williamson, R, Ramsay, L E, Yeo, W W, Jackson, P R, Miettinen, T. A, Gylling, H., Strandberg, T., Sarna, S. (1998). Cholestanol and survival with simvastatin. BMJ 317: 1252-1252 [Full text]  

Rapid Responses:

Read all Rapid Responses

Cholestanol and survival with simvastatin: the missing link
Erica Wallis
bmj.com, 28 May 1998 [Full text]
Access jobs at BMJ Careers
Whats new online at Student BMJ